Use of IRE1α-XBP1 signaling pathway biomarkers for modulating immune responses

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 12227548
APP PUB NO 20220023341A1
SERIAL NO

17294477

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention is based, in part, on the identification of an IRE1α-XBP1-cMyc axis in NK cell immunity. The present invention provides compositions and methods for treating conditions that would benefit from modulating (e.g., upregulating or downregulating) an immune response using an agent that modulates the IRE1α-XBP1 pathway, or a composition comprising modified NK cells.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • DANA-FARBER CANCER INSTITUTE, INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Dong, Han Boston, US 3 0
Glimcher, Laurie H Boston, US 70 397

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Aug 18, 2028
7.5 Year Payment $3600.00 $1800.00 $900.00 Aug 18, 2032
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 18, 2036
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00